Plicamycin

This classification denotes an antineoplastic antibiotic and dna minor groove binding agent and bone resorption inhibitor with the molecular formula C52H76O24, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NIJ123W41V, chemically known as 1(2h)-anthracenone, 6-((2,6-dideoxy-3-o-(2,6-dideoxy-beta-d-arabino-hexopyranosyl)-beta-d-arabino-h)-2-((o-2,6-dideoxy-3-c-methyl-beta-d-ribohexopyranosyl-(1,4)-o-2,6-dideoxy-alpha-d-lyxo-hexpyranosyl-(1-3)-2,6-dideoxy-beta-d-arabino-hexpyranosyl)oxy)-3-(3,4-dihydroxy-1-methoxy-2-oxopentyl)-3,4-dihydro-8,9-dihydroxy-7-methyl-, (2s-alpha,3beta(1r*,3r*4s*)))- but generally known as plicamycin, which bears US NIH Compound Identifier 29051. European Medicines Agency schedules Plicamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09959MIG. The term PLICAMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules plicamycin in its Anatomical Therapeutic Chemical (ATC) Classification. PLICAMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule plicamycin under HS 29419000 and SITC 54139. As of Q4 2014, PLICAMYCIN remains the US FDA Preferred Term for this commodity. Plicamycin bears US NLM identifiers UMLS ID C0026234 and NCI Concept Code C658. SMILES: O(C1CC(OC2C(CC3C(C2=O)C(O)C2C(C3)CC(OC3OC(C(O)C(OC4OC(C(O)C(O)C4)C)C3)C)C(C2O)C)C(OC)C(=O)C(O)C(O)C)OC(C1O)C)C1OC(C(O)C(OC2OC(C(O)C(O)(C2)C)C)C1)C.